GCP
LEGN icon

GSA Capital Partners’s Legend Biotech LEGN Stock Holding History

GSA Capital Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Buy
84,765
+69,882
+470% +$1.33M 0.1% 272
2025
Q4 		$324K Buy
+14,883
New +$426K 0.03% 1128
2023
Q3 		– Sell
-12,296
Closed -$849K – 1726
2023
Q2 		$849K Buy
+12,296
New +$803K 0.08% 409
2021
Q4 		– Sell
-6,104
Closed -$309K – 1623
2021
Q3 		$309K Buy
+6,104
New +$254K 0.03% 997

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GSA Capital Partners's LEGN Position: Q1 2026 in Review

GSA Capital Partners increased its Legend Biotech (LEGN) stake by 470% in Q1 2026, buying an estimated $1.33M and bringing the position to 84,765 shares worth $1.53M. The position accounts for 0.1% of the portfolio, ranked #272.

GSA Capital Partners first reported a position in LEGN in Q3 2021 and has held it in 4 quarters since. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • GSA Capital Partners held 84,765 shares of Legend Biotech worth $1.53M as of Q1 2026.
  • GSA Capital Partners bought 69,882 Legend Biotech shares in Q1 2026, an estimated $1.33M.
  • Legend Biotech made up 0.1% of GSA Capital Partners's portfolio in Q1 2026, its #272 holding.
  • GSA Capital Partners first reported a position in Legend Biotech in Q3 2021 and has held it in 4 quarters since.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.